Matches in SemOpenAlex for { <https://semopenalex.org/work/W2341021072> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2341021072 endingPage "16021" @default.
- W2341021072 startingPage "16021" @default.
- W2341021072 abstract "16021 Background: The FOSI is a very brief(8-item) index derived from the FACT-O to measure symptom response to treatment for ovarian cancer(OC). We evaluated its performance in a single arm Phase II clinical trial. Methods: The FOSI was administered to patients with advanced OC participating in a single arm Ph II clinical trial of pertuzumab(Gordon et al, JCO (2006) v24:4324;2006)). Pertuzumab, a humanized HER2 antibody is the first in a new class of investigational agents known as HER dimerization inhibitors(HDIs). Patients completed the FOSI at D1 of each 3 week cycle, up to 17 cycles. Validation analyses focused on data from the first 4 cycles and included Cronbach's alpha coefficients plus cross-sectional and longitudinal comparisons of groups defined by ECOG performance status (PS). Results: 62 patients completed the FOSI at baseline (B), 54 at cycle 2, 44 at cycle 3 and 27 at cycle 4. The FOSI showed acceptable internal consistency reliability with alphas of 0.73 to 0.80. The FOSI differentiated patients with PS 0 from those with PS =1 at each cycle (Table). There was a difference in FOSI scores in patients with worsened PS from those whose PS improved or was unchanged at cycle 2 only (p<0.001). The ES (mean change/ SD of change scores) for the group with worsened PS was -0.77. The minimally important difference was estimated to be 2–3 points. Conclusions: The FOSI is a valid symptom measure in this population of OC patients, demonstrating acceptable reliability, validity and responsiveness to clinical change. [Table: see text] No significant financial relationships to disclose." @default.
- W2341021072 created "2016-06-24" @default.
- W2341021072 creator A5011339598 @default.
- W2341021072 creator A5025063215 @default.
- W2341021072 creator A5039180386 @default.
- W2341021072 creator A5044492888 @default.
- W2341021072 creator A5049851359 @default.
- W2341021072 creator A5072015843 @default.
- W2341021072 creator A5082993956 @default.
- W2341021072 date "2007-06-20" @default.
- W2341021072 modified "2023-09-25" @default.
- W2341021072 title "Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer" @default.
- W2341021072 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.16021" @default.
- W2341021072 hasPublicationYear "2007" @default.
- W2341021072 type Work @default.
- W2341021072 sameAs 2341021072 @default.
- W2341021072 citedByCount "6" @default.
- W2341021072 countsByYear W23410210722014 @default.
- W2341021072 countsByYear W23410210722019 @default.
- W2341021072 countsByYear W23410210722020 @default.
- W2341021072 countsByYear W23410210722022 @default.
- W2341021072 countsByYear W23410210722023 @default.
- W2341021072 crossrefType "journal-article" @default.
- W2341021072 hasAuthorship W2341021072A5011339598 @default.
- W2341021072 hasAuthorship W2341021072A5025063215 @default.
- W2341021072 hasAuthorship W2341021072A5039180386 @default.
- W2341021072 hasAuthorship W2341021072A5044492888 @default.
- W2341021072 hasAuthorship W2341021072A5049851359 @default.
- W2341021072 hasAuthorship W2341021072A5072015843 @default.
- W2341021072 hasAuthorship W2341021072A5082993956 @default.
- W2341021072 hasConcept C106906290 @default.
- W2341021072 hasConcept C121608353 @default.
- W2341021072 hasConcept C126322002 @default.
- W2341021072 hasConcept C143998085 @default.
- W2341021072 hasConcept C171606756 @default.
- W2341021072 hasConcept C2780427987 @default.
- W2341021072 hasConcept C2908647359 @default.
- W2341021072 hasConcept C31760486 @default.
- W2341021072 hasConcept C535046627 @default.
- W2341021072 hasConcept C70410870 @default.
- W2341021072 hasConcept C71924100 @default.
- W2341021072 hasConcept C99454951 @default.
- W2341021072 hasConceptScore W2341021072C106906290 @default.
- W2341021072 hasConceptScore W2341021072C121608353 @default.
- W2341021072 hasConceptScore W2341021072C126322002 @default.
- W2341021072 hasConceptScore W2341021072C143998085 @default.
- W2341021072 hasConceptScore W2341021072C171606756 @default.
- W2341021072 hasConceptScore W2341021072C2780427987 @default.
- W2341021072 hasConceptScore W2341021072C2908647359 @default.
- W2341021072 hasConceptScore W2341021072C31760486 @default.
- W2341021072 hasConceptScore W2341021072C535046627 @default.
- W2341021072 hasConceptScore W2341021072C70410870 @default.
- W2341021072 hasConceptScore W2341021072C71924100 @default.
- W2341021072 hasConceptScore W2341021072C99454951 @default.
- W2341021072 hasIssue "18_suppl" @default.
- W2341021072 hasLocation W23410210721 @default.
- W2341021072 hasOpenAccess W2341021072 @default.
- W2341021072 hasPrimaryLocation W23410210721 @default.
- W2341021072 hasRelatedWork W1608269846 @default.
- W2341021072 hasRelatedWork W182989684 @default.
- W2341021072 hasRelatedWork W2353260778 @default.
- W2341021072 hasRelatedWork W2470887676 @default.
- W2341021072 hasRelatedWork W2566967253 @default.
- W2341021072 hasRelatedWork W2786173563 @default.
- W2341021072 hasRelatedWork W2789668336 @default.
- W2341021072 hasRelatedWork W4252834862 @default.
- W2341021072 hasRelatedWork W4254874562 @default.
- W2341021072 hasRelatedWork W4327944896 @default.
- W2341021072 hasVolume "25" @default.
- W2341021072 isParatext "false" @default.
- W2341021072 isRetracted "false" @default.
- W2341021072 magId "2341021072" @default.
- W2341021072 workType "article" @default.